{"id":"tt-vaccine","safety":{"commonSideEffects":[{"rate":"null","effect":"Pain, redness, or swelling at the injection site"}]},"_chembl":{"chemblId":"CHEMBL3975020","moleculeType":"Small molecule","molecularWeight":"475.60"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This is achieved through the introduction of inactivated diphtheria and tetanus toxins, which trigger an immune response and provide long-term protection against these diseases.","oneSentence":"The TT vaccine works by stimulating the body to produce antibodies against diphtheria and tetanus toxins.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:51:01.936Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of diphtheria and tetanus"}]},"trialDetails":[{"nctId":"NCT03650114","phase":"PHASE3","title":"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2018-12-28","conditions":"Relapsing Multiple Sclerosis","enrollment":1882},{"nctId":"NCT07017777","phase":"PHASE3","title":"A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks)","status":"RECRUITING","sponsor":"CanSino Biologics Inc.","startDate":"2025-11-14","conditions":"Pneumococcal Infections, Streptococcal Infections, Bacterial Infections","enrollment":600},{"nctId":"NCT05092386","phase":"PHASE1","title":"Safety and Immunogenicity Study of a 13-valent Pneumococcal Polysaccharide Conjugate Vaccine","status":"COMPLETED","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2023-01-03","conditions":"Pneumococcal Infections","enrollment":310},{"nctId":"NCT05856396","phase":"PHASE4","title":"Maternal Determinants of Infant Immunity to Pertussis","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire Saint Pierre","startDate":"2023-09-12","conditions":"Vaccination; Infection, Maternal-Fetal Relations, Pertussis","enrollment":200},{"nctId":"NCT07197762","phase":"PHASE4","title":"MenB-FHbp or MenACWY-TT/MenB-FHbp Vaccine in MenB-4C Primed Young Adults","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-11-04","conditions":"Neisseria Meningitidis","enrollment":125},{"nctId":"NCT05929651","phase":"PHASE4","title":"Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2023-09-07","conditions":"Meningococcal Immunisation, Healthy Volunteers","enrollment":71},{"nctId":"NCT06879327","phase":"PHASE2","title":"Infant Malaria Vaccine Schedule Optimization","status":"RECRUITING","sponsor":"PATH","startDate":"2025-05-30","conditions":"Malaria Vaccines","enrollment":1200},{"nctId":"NCT05082285","phase":"PHASE2","title":"A Study on the Safety, Tolerability and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-11-29","conditions":"Infections, Meningococcal","enrollment":724},{"nctId":"NCT06939777","phase":"PHASE1, PHASE2","title":"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SNA02-48 Injection in Chinese Adult Participants","status":"NOT_YET_RECRUITING","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2025-04","conditions":"Tetanus","enrollment":255},{"nctId":"NCT05093829","phase":"PHASE3","title":"Meningococcal Serogroup ACYWX Conjugate Vaccine in Comparison With MenACWY-TT Conjugate Vaccine","status":"COMPLETED","sponsor":"Emory University","startDate":"2022-03-24","conditions":"Meningitis","enrollment":1325},{"nctId":"NCT05490329","phase":"NA","title":"Addressing Vaccine Hesitancy and Increasing COVID-19 Vaccine Uptake Among African American Young Adults in the South","status":"COMPLETED","sponsor":"Florida State University","startDate":"2023-03-13","conditions":"COVID-19, Vaccine Uptake","enrollment":360},{"nctId":"NCT06608199","phase":"PHASE3","title":"A Phase 3 Study to Evaluate the Immunogenicity and Safety of Minhai's PCV13-DT/TT Vaccine As Compared to Pfizer's PCV13 Vaccine","status":"RECRUITING","sponsor":"Beijing Minhai Biotechnology Co., Ltd","startDate":"2024-11-01","conditions":"Pneumococcal Vaccines, Pneumococcal Infections","enrollment":500},{"nctId":"NCT02960230","phase":"PHASE1, PHASE2","title":"H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas","status":"COMPLETED","sponsor":"Sabine Mueller, MD, PhD","startDate":"2016-11-18","conditions":"Diffuse Intrinsic Pontine Glioma, Glioma, Diffuse Midline Glioma, H3 K27M-Mutant","enrollment":50},{"nctId":"NCT06120751","phase":"PHASE3","title":"A Clinical Trial to Evaluate the Safety and Immunogenicity of a Single Dose of Adsorbed Tetanus Vaccine in a Population Aged 18 Years and Over","status":"COMPLETED","sponsor":"CanSino Biologics Inc.","startDate":"2024-03-20","conditions":"Tetanus","enrollment":1000},{"nctId":"NCT06123663","phase":"PHASE1","title":"A Study to Evaluate the Safety and Immunogenicity of a Single Dose of Adsorbed Tetanus Vaccine in a Population Aged 18 Years and Over","status":"COMPLETED","sponsor":"CanSino Biologics Inc.","startDate":"2023-12-20","conditions":"Tetanus","enrollment":60},{"nctId":"NCT05934890","phase":"PHASE3","title":"A Phase 3 Study to Evaluate the Immunogenicity and Safety of Walvax's PCV13-TT as Compared to Pfizer's PCV13","status":"ACTIVE_NOT_RECRUITING","sponsor":"Walvax Biotechnology Co., Ltd.","startDate":"2023-11-23","conditions":"Pneumococcal Disease, Invasive","enrollment":630},{"nctId":"NCT03848182","phase":"PHASE2","title":"Analyzing Childhood Recall Antigens in Patients With Pancreatic Cancer","status":"TERMINATED","sponsor":"Albert Einstein College of Medicine","startDate":"2017-07-21","conditions":"Pancreatic Cancer","enrollment":10},{"nctId":"NCT06360250","phase":"EARLY_PHASE1","title":"Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of the Fully Human Anti-tetanus Toxin Monoclonal Antibody A82 / B86 Injection Combination Formulation","status":"NOT_YET_RECRUITING","sponsor":"Changchun BCHT Biotechnology Co.","startDate":"2024-04-10","conditions":"Clostridium Tetanus","enrollment":190},{"nctId":"NCT04841369","phase":"PHASE3","title":"Phase III Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above (PICTPCV13i)","status":"COMPLETED","sponsor":"CanSino Biologics Inc.","startDate":"2021-04-13","conditions":"Pneumococcal Infections, Streptococcal Infections, Bacterial Infections","enrollment":3420},{"nctId":"NCT02545868","phase":"PHASE3","title":"A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-10-27","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":102},{"nctId":"NCT04819113","phase":"PHASE3","title":"Study to Evaluate the Safety and Immunogenicity of Nimenrix (Registered) in Healthy Infants, Given at 3 and 12 Months of Age","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-04-09","conditions":"Meningococcal Vaccine","enrollment":149},{"nctId":"NCT02700841","phase":"PHASE2","title":"Enhancing Anti--Tetanus Vaccine Response After Autologous Stem Cell Transplantation","status":"TERMINATED","sponsor":"University of Nebraska","startDate":"2020-01-09","conditions":"Plasma Cell Myeloma","enrollment":8},{"nctId":"NCT06302374","phase":"PHASE1, PHASE2","title":"Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of GR2001 in Chinese Healthy Adults","status":"COMPLETED","sponsor":"Genrix (Shanghai) Biopharmaceutical Co., Ltd.","startDate":"2023-03-04","conditions":"Tetanus","enrollment":202},{"nctId":"NCT04852185","phase":"PHASE4","title":"Evaluation of Typhoid Conjugate Vaccine Effectiveness in Ghana","status":"RECRUITING","sponsor":"International Vaccine Institute","startDate":"2021-08-24","conditions":"Typhoid Fever","enrollment":23000},{"nctId":"NCT05771779","phase":"PHASE3","title":"Co-administration Study of OCV, TCV and MR","status":"UNKNOWN","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2023-10-14","conditions":"Typhoid, Cholera, Measles","enrollment":2117},{"nctId":"NCT05119426","phase":"PHASE4","title":"Effectiveness of a Typhoid Conjugate Vaccine in DRC","status":"UNKNOWN","sponsor":"International Vaccine Institute","startDate":"2022-02-11","conditions":"Typhoid Fever","enrollment":48000},{"nctId":"NCT04100772","phase":"PHASE1","title":"Phase I Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above","status":"COMPLETED","sponsor":"CanSino Biologics Inc.","startDate":"2020-05-18","conditions":"Pneumococcal Infections, Streptococcal Infections, Bacterial Infections","enrollment":237},{"nctId":"NCT05095844","phase":"","title":"National Vaccine Adverse Event Reporting Survey and Etiology","status":"UNKNOWN","sponsor":"Neuroganics LLC","startDate":"2022-03-15","conditions":"COVID-19, Vaccine Adverse Reaction, Vaccine Reaction","enrollment":100000},{"nctId":"NCT03606096","phase":"PHASE4","title":"Gambia Pertussis Study (GaPs)","status":"UNKNOWN","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2019-01-23","conditions":"Pertussis","enrollment":600},{"nctId":"NCT03694405","phase":"PHASE4","title":"Adolescent MenACWY Booster Study","status":"COMPLETED","sponsor":"Canadian Immunization Research Network","startDate":"2018-09-20","conditions":"Meningococcal Disease, Invasive","enrollment":244},{"nctId":"NCT02747407","phase":"","title":"Qualitative, Qualitative, and Functional Studies Over the First Year in Measuring Immune System Response During the First Year of Therapy in Patients With Brain Tumors","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2016-05","conditions":"Astrocytoma, Glioma, Oligodendroglioma","enrollment":55},{"nctId":"NCT01939158","phase":"PHASE3","title":"Immunogenicity and Safety Study of 1 and 2 Doses of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine MenACWY-TT (GSK134612) in Toddlers, Persistence up to 5 Years After Vaccination and Co-administration With Pfizer's Prevenar 13™Vaccine","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-10-02","conditions":"Infections, Meningococcal","enrollment":803},{"nctId":"NCT03554213","phase":"","title":"Typhoid Conjugate Vaccine Introduction in Navi Mumbai, India","status":"COMPLETED","sponsor":"Stanford University","startDate":"2018-07-02","conditions":"Enteric Fever, Typhoid Fever, Salmonella Typhi Infection","enrollment":17292},{"nctId":"NCT03189745","phase":"PHASE3","title":"A Study To Evaluate A Booster Dose Of Menacwy-tt Vaccine Administered 10 Years After Healthy Subjects Aged 11-17 Years Received Either Menacwy-tt Vaccine (Nimenrix(Registered)) Or Mencevax Acwy(Registered).","status":"COMPLETED","sponsor":"Pfizer","startDate":"2017-08-01","conditions":"Meningococcal ACWY Disease","enrollment":229},{"nctId":"NCT01896596","phase":"PHASE4","title":"Hepatitis B Vaccination in Infants","status":"COMPLETED","sponsor":"Public Health England","startDate":"2013-07","conditions":"Meningococcal Disease, Pneumococcal Disease, Haemophilus Influenzae Serotype b Disease","enrollment":300},{"nctId":"NCT01192997","phase":"PHASE2, PHASE3","title":"Comparison of Two Meningococcal ACWY Conjugate Vaccines","status":"COMPLETED","sponsor":"Public Health England","startDate":"2012-06","conditions":"Meningococcal Meningitis","enrollment":91},{"nctId":"NCT03063736","phase":"EARLY_PHASE1","title":"Entolimod, an Adjuvant for Vaccine Augmentation","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2017-12-08","conditions":"Substance Use Disorders","enrollment":40},{"nctId":"NCT00136604","phase":"PHASE3","title":"Response to GSK Biologicals' Tritanrix-HepB/Hib-MenAC Vacc (4th Dose) at 15-24m & Mencevax ACWY at 24-30m","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-01-22","conditions":"Whole Cell Pertussis, Haemophilus Influenzae Type b, Hepatitis B","enrollment":617},{"nctId":"NCT00228917","phase":"PHASE3","title":"Safety Study of Tritanrix-HepB/Hib-MenAC, Tritanrix-HepB/Hiberix, and Mencevax ACWY Vaccines in Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-06-16","conditions":"Whole Cell Pertussis, Tetanus, Hepatitis B","enrollment":798},{"nctId":"NCT00795457","phase":"EARLY_PHASE1","title":"Effects of Vaccinations With HLA-A2-Restricted Glioma Antigen-Peptides in Combination With Poly-ICLC for Adults With High-Risk WHO Grade II Astrocytomas and Oligo-Astrocytomas","status":"COMPLETED","sponsor":"Ian F. Pollack, M.D.","startDate":"2009-01","conditions":"Astrocytoma, Oligo-Astrocytoma, Glioma","enrollment":13},{"nctId":"NCT01934140","phase":"PHASE3","title":"Study to Evaluate the Long-term Antibody Persistence of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine (GSK134612) Versus Mencevax ACWY in Healthy Adolescents and Adults and Booster Response to MenACWY-TT Vaccine Administered at 10 Years Post-primary Vaccination","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-04","conditions":"Infections, Meningococcal","enrollment":311},{"nctId":"NCT01900899","phase":"PHASE3","title":"Persistence of Antibodies After Meningococcal Vaccine PF-06866681 in Healthy Children","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-07","conditions":"Infections, Meningococcal","enrollment":184},{"nctId":"NCT01962207","phase":"PHASE3","title":"The Long-term Antibody Persistence of MenACWY-TT Vaccine (PF-06866681) Versus Meningitec(Registered) or Mencevax(Registered) ACWY in Healthy Adolescents and Adults and a Booster Dose of MenACWY-TT Administered 10 Years Post Primary Vaccination","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-10","conditions":"Infections, Meningococcal","enrollment":243},{"nctId":"NCT01553279","phase":"PHASE3","title":"Immunogenicity and Safety of V419 (PR51) in Combination With MCC in Infants and Toddlers (V419-011)","status":"COMPLETED","sponsor":"MCM Vaccines B.V.","startDate":"2012-03-30","conditions":"Neisseria Meningitidis, Bacterial Infections, Virus Diseases","enrollment":284},{"nctId":"NCT01777308","phase":"PHASE3","title":"Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine Administered 6 Years Post-MenC Primary Vaccination in Healthy Subjects Who Were 12-18 Months at Primary Vaccination","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-05-03","conditions":"Infections, Meningococcal","enrollment":156},{"nctId":"NCT02286895","phase":"PHASE4","title":"Immune Response to Rotavirus Vaccine After a Supplemental Dose Given at 9 Months of Age With Local EPI Vaccines in Mali","status":"COMPLETED","sponsor":"PATH","startDate":"2014-10","conditions":"Diarrhea Rotavirus","enrollment":600},{"nctId":"NCT00614614","phase":"PHASE3","title":"Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-02-13","conditions":"Infections, Meningococcal","enrollment":1558},{"nctId":"NCT01978093","phase":"PHASE3","title":"Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-02-01","conditions":"Neisseria Meningitidis, Haemophilus Influenzae Type b","enrollment":600},{"nctId":"NCT00127855","phase":"PHASE2","title":"Dose Ranging Study of Combined Haemophilus Influenzae Type B-Meningococcal Serogroups CY (Hib-MenCY-TT) Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-03-01","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":409},{"nctId":"NCT00129116","phase":"PHASE2","title":"3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine Compared to Licensed Meningococcal Serogroup C Conjugate Vaccine, Each Administered at 2,3,4 Mths of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-03-01","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":388},{"nctId":"NCT00129129","phase":"PHASE2","title":"Comparison of GSKBiologicals' Hib-MenCY-TT Vaccine vs Licensed Hib Conjugate or Meningococcal Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-08-01","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":756},{"nctId":"NCT00289783","phase":"PHASE3","title":"Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-02-22","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":4441},{"nctId":"NCT00134719","phase":"PHASE2","title":"Hib-MenCY-TT Vaccine Study Compared to Licensed Hib and Meningococcal Serogroup C Conjugate Vaccines","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-04-11","conditions":"Neisseria Meningitidis, Haemophilus Influenzae Type b","enrollment":1104},{"nctId":"NCT00196976","phase":"PHASE2","title":"Safety & Immunogenicity of 1 Dose of GSK134612 in Children 12-14 Months and 3-5 Years Old","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-03-24","conditions":"Infections, Meningococcal","enrollment":461},{"nctId":"NCT00871338","phase":"PHASE2","title":"Study to Evaluate GSK Biologicals' GSK2197870A Vaccine Given as Primary Course in Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-06-24","conditions":"Neisseria Meningitidis, Haemophilus Influenzae Type b","enrollment":284},{"nctId":"NCT00000105","phase":"","title":"Vaccination With Tetanus and KLH to Assess Immune Responses.","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2002-07","conditions":"Cancer","enrollment":112},{"nctId":"NCT01767376","phase":"PHASE3","title":"Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Conjugate Vaccine (GSK134612) When Co-administered With Boostrix® in Subjects Between 11 and 25 Years of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-01-10","conditions":"Infections, Meningococcal","enrollment":692},{"nctId":"NCT00345579","phase":"PHASE3","title":"Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-09","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":4432},{"nctId":"NCT00359983","phase":"PHASE3","title":"Long-Term Antibody Persistence at 1, 3 and 5 Years After a Fourth Dose of GSK Biologicals' Hib-MenCY-TT Vaccine Compared to ActHIB","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-09","conditions":"Neisseria Meningitidis, Haemophilus Influenzae Type b","enrollment":270},{"nctId":"NCT00345683","phase":"PHASE3","title":"Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-07","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":4021},{"nctId":"NCT00126984","phase":"PHASE2","title":"Study in Children to Evaluate the Immunogenicity and Safety of 4 Formulations of GSK Bio MenACWY-TT Conjugate Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-07","conditions":"Infections, Meningococcal","enrollment":508},{"nctId":"NCT00135486","phase":"PHASE2","title":"Study to Evaluate GlaxoSmithKline (GSK) Biologicals' MenC-TT Vaccine and Hib-MenC-TT Vaccine in Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2002-03","conditions":"Infections, Meningococcal","enrollment":500},{"nctId":"NCT00135564","phase":"PHASE2","title":"Study to Evaluate GlaxoSmithKline (GSK) Biologicals' MenC-TT and Hib-MenC-TT or Meningitec™ in Healthy Toddlers","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-01","conditions":"Infections, Meningococcal","enrollment":500},{"nctId":"NCT00874861","phase":"EARLY_PHASE1","title":"HLA-A2-Restricted Glioma Antigen-Peptides Vaccinations With Poly-ICLC for Recurrent WHO Grade II Gliomas","status":"COMPLETED","sponsor":"Ian F. Pollack, M.D.","startDate":"2009-04","conditions":"Astrocytoma, Oligoastrocytoma, Oligodendroglioma","enrollment":10},{"nctId":"NCT02139228","phase":"PHASE3","title":"Persistency Study After Hib-CRM (Cross-Reacting Material)197 or Hib-TT (Tetanus Toxoid) Vaccines in Chinese Children","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2014-11","conditions":"Meningitis, Epiglottitis, Pneumonia, Arthritis Caused by Haemophilus Influenzae Type b","enrollment":426},{"nctId":"NCT01129518","phase":"PHASE4","title":"Can we Reduce the Number of Vaccine Injections for Children?","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2010-06","conditions":"Invasive Meningococcal Disease","enrollment":404},{"nctId":"NCT01994629","phase":"PHASE2","title":"Safety and Immunogenicity of One Dose of Novartis' Meningococcal ACWY-CRM Vaccine and GlaxoSmithKline Biologicals' Meningococcal ACWY-TT Vaccine in Healthy Toddlers","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2013-11","conditions":"Meningococcal Disease","enrollment":202},{"nctId":"NCT00617760","phase":"PHASE3","title":"Safety and Immunogenicity Study of MenC-TT Vaccine (NeisVac-C) in Toddlers Previously Immunized With PCV7 (Prevenar®)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-03","conditions":"Neisseria Meningitidis (Bacterial Meningitis), Invasive Pneumococcal Disease (IPD)","enrollment":330},{"nctId":"NCT00161928","phase":"PHASE3","title":"Study of NeisVac-C Vaccine to Evaluate Immunological Interference With Hepatitis B, Inactivated Polio and Acellular Pertussis Vaccines in Healthy Infants","status":"COMPLETED","sponsor":"Pfizer","startDate":"2002-04","conditions":"Meningitis, Meningococcal","enrollment":330},{"nctId":"NCT00128219","phase":"PHASE2","title":"Prevention of GBS Colonization Via Immunity","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-07","conditions":"Beta Haemolytic Streptococcal Infection","enrollment":667},{"nctId":"NCT00715910","phase":"PHASE2","title":"The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Adolescents/Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-07","conditions":"Infections, Meningococcal","enrollment":818},{"nctId":"NCT01986335","phase":"PHASE3","title":"Protectivity and Safety of DTP/HB/Hib (Bio Farma) Vaccines in Infants, Batch Consistency, Multi Center Trial","status":"COMPLETED","sponsor":"PT Bio Farma","startDate":"2012-08","conditions":"Healthy","enrollment":600},{"nctId":"NCT01986322","phase":"PHASE2","title":"Immunogenicity and Safety of DTP/HB/Hib (Bio Farma)Compared to DTP/HB Given Simultaneously With Hib(Registered)Vaccine","status":"COMPLETED","sponsor":"PT Bio Farma","startDate":"2011-07","conditions":"Healthy","enrollment":220},{"nctId":"NCT01977196","phase":"PHASE1","title":"The Safety and Immunogenicity of DTP/Hepatitis B 10ug Hib Vaccine (Bio Farma)","status":"COMPLETED","sponsor":"PT Bio Farma","startDate":"2011-04","conditions":"Healthy","enrollment":30},{"nctId":"NCT00392808","phase":"PHASE4","title":"Immunogenicity of the Booster Dose of Two MenC Vaccines","status":"COMPLETED","sponsor":"Centro Superior de Investigación en Salud Publica","startDate":"2007-01","conditions":"Meningococcal Infection","enrollment":389},{"nctId":"NCT00342628","phase":"PHASE2","title":"Safety, Immunogenicity and Compatibility With DTP of a Typhoid Fever Vaccine in Infants","status":"COMPLETED","sponsor":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","startDate":"2006-07","conditions":"Typhoid Fever","enrollment":301},{"nctId":"NCT00008853","phase":"PHASE1","title":"Evaluation of Two Type III GBS Polysaccharide-Tetanus Toxoid Conjugate Vaccines","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"Bacterial Infections, Group B Streptococcus","enrollment":65}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":192,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"TT Vaccine","genericName":"TT Vaccine","companyName":"Hoffmann-La Roche","companyId":"roche","modality":"Biologic","firstApprovalDate":"","aiSummary":"The TT Vaccine, also known as Hib-MenCY-TT, is a conjugate vaccine that protects against Haemophilus influenzae type b, Neisseria meningitidis serogroups C and Y, and pertussis. It is a small molecule vaccine that has been studied in clinical trials for safety and efficacy in infants as young as 12 to 15 months old.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}